Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN W MCCONNELL

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1902831761
CMS profile
40381
Location
LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$121,291.06

109 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN W MCCONNELL

NPI 1902831761 · CMS profile ID 40381

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1902831761?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN W MCCONNELL, NPI 1902831761, CMS profile ID 40381. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1902831761?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JOHN W MCCONNELL, NPI 1902831761, CMS profile ID 40381. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1902831761?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JOHN W MCCONNELL, NPI 1902831761, CMS profile ID 40381, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1902831761?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

109 matching records · $121,291.06 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 109 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–109 of 109.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Actelion Pharmaceuticals US, Inc. $121.8203/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885390853 CMS
Actelion Pharmaceuticals US, Inc. $222.9003/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885390855 CMS
Actelion Pharmaceuticals US, Inc. $4,340.0002/28/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885390869 CMS
Actelion Pharmaceuticals US, Inc. $4,340.0002/24/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885390833 CMS
Bayer HealthCare Pharmaceuticals Inc. $90.0002/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929850857 CMS
Actelion Pharmaceuticals US, Inc. $1,240.0001/26/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885390823 CMS
Actelion Pharmaceuticals US, Inc. $111.6201/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885390929 CMS
Actelion Pharmaceuticals US, Inc. $19.1501/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885390931 CMS
Bayer HealthCare Pharmaceuticals Inc. $956.0001/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929842213 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $162,632.03 216
PY2020 $55,908.73 73
PY2021 $51,218.78 46
PY2022 $121,291.06 109
PY2023 $146,361.81 129
PY2024 $140,087.04 155
PY2025 $186,945.54 194

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $628,069.55 56
PY2024 Principal investigator $890,582.96 49
PY2023 Recipient $1,159.37 1
PY2023 Principal investigator $285,471.40 29
PY2022 Principal investigator $252,421.74 11
PY2021 Principal investigator $167,628.46 24
PY2020 Principal investigator $204,781.37 27
PY2019 Principal investigator $243,121.25 36

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

56 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $116,744.44 12/31/2025 Non-covered Recipient Entity
Norton Pulmonary Specialists
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension PAH World Health Organization WHO Functional Class FC III o No dispute reported 06/30/2026 1232917471
Principal investigator 1 Merck Sharp & Dohme LLC $19,869.90 12/31/2025 Non-covered Recipient Entity
Norton Pulmonary Specialists
An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH MK-7962-038 No dispute reported 06/30/2026 1232934250
Principal investigator 1 Merck Sharp & Dohme LLC $6,592.43 12/31/2025 Non-covered Recipient Entity
Norton Pulmonary Specialists
An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH MK-7962-038 No dispute reported 06/30/2026 1232934252
Principal investigator 1 Merck Sharp & Dohme LLC $28,028.29 12/31/2025 Non-covered Recipient Entity
Norton Pulmonary Specialists
A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection Fraction HFpEF No dispute reported 06/30/2026 1232938096
Principal investigator 1 Merck Sharp & Dohme LLC $12,032.58 12/31/2025 Non-covered Recipient Entity
Norton Pulmonary Specialists
A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection Fraction HFpEF No dispute reported 06/30/2026 1232938098
Principal investigator 1 Merck Sharp & Dohme LLC $180,119.46 12/31/2025 Covered Recipient Teaching Hospital
Norton Hospitals Inc
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection F No dispute reported 06/30/2026 1232938440
Principal investigator 1 Merck Sharp & Dohme LLC $11,829.50 12/31/2025 Non-covered Recipient Entity
Norton Pulmonary Specialists
A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept MK-7962 Administered Using Either a Weight-based or Weight-banded Approach in Participants With Pulmonary Arterial Hypertension PAH on No dispute reported 06/30/2026 1232938902
Principal investigator 1 United Therapeutics Corporation $1,592.96 12/24/2025 Non-covered Recipient Entity
Norton Healthcare Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242387051
Principal investigator 1 United Therapeutics Corporation $1,617.28 12/24/2025 Non-covered Recipient Entity
Norton Healthcare Inc
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242387069
Principal investigator 1 Merck Sharp & Dohme LLC $23,201.00 12/17/2025 Non-covered Recipient Entity
Norton Pulmonary Specialists
A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection Fraction HFpEF No dispute reported 06/30/2026 1232938768
Principal investigator 1 United Therapeutics Corporation $300.00 12/10/2025 Non-covered Recipient Entity
Norton Healthcare Inc
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242387061
Principal investigator 1 Janssen Research & Development, LLC $1,444.00 12/01/2025 Non-covered Recipient Entity
COMMUNITY MEDICAL ASSOCIATES INC DB
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175395823
Principal investigator 1 United Therapeutics Corporation $1,425.28 11/26/2025 Non-covered Recipient Entity
Norton Healthcare Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242387049
Principal investigator 1 United Therapeutics Corporation $1,447.04 11/26/2025 Non-covered Recipient Entity
Norton Healthcare Inc
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242387067
Principal investigator 1 United Therapeutics Corporation $4,695.04 11/12/2025 Non-covered Recipient Entity
Norton Healthcare Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242387059
Principal investigator 1 United Therapeutics Corporation $1,000.00 11/12/2025 Non-covered Recipient Entity
Norton Healthcare Inc
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242387063
Principal investigator 1 United Therapeutics Corporation $4,766.72 11/12/2025 Non-covered Recipient Entity
Norton Healthcare Inc
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242387075
Principal investigator 1 United Therapeutics Corporation $7,766.54 11/12/2025 Non-covered Recipient Entity
Norton Healthcare Inc
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242387085
Principal investigator 1 Novartis Pharmaceuticals Corporation $14,446.68 11/03/2025 Non-covered Recipient Entity
NORTON INFECTIOUS DISEASES SPECIALISTS
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of LTP001 in Healthy Adult Participants (Part A) and to Evaluate the Efficacy and Safety of LTP001 for th No dispute reported 06/30/2026 1190308860
Principal investigator 1 Janssen Research & Development, LLC $181.00 10/30/2025 Non-covered Recipient Entity
COMMUNITY MEDICAL ASSOCIATES INC DB
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175395859
Principal investigator 1 Janssen Research & Development, LLC $1,344.00 09/04/2025 Non-covered Recipient Entity
COMMUNITY MEDICAL ASSOCIATES INC DB A NORTON NEUROSCIENCE INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175395801
Principal investigator 1 Janssen Research & Development, LLC $124.00 08/29/2025 Non-covered Recipient Entity
COMMUNITY MEDICAL ASSOCIATES INC DB A NORTON NEUROSCIENCE INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175395841
Principal investigator 1 United Therapeutics Corporation $156.94 08/13/2025 Non-covered Recipient Entity
Norton Healthcare Inc
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242387081
Principal investigator 1 United Therapeutics Corporation $8,650.00 08/13/2025 Non-covered Recipient Entity
Norton Healthcare Inc
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242387087
Principal investigator 1 Merck Sharp & Dohme LLC $2,532.72 07/30/2025 Covered Recipient Teaching Hospital
Norton Hospitals Inc
An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH No dispute reported 06/30/2026 1232938818
Principal investigator 1 PFIZER INC. $17,479.75 07/25/2025 Non-covered Recipient Entity
Norton Healthcare Inc
A PHASE 1 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE ESCALATING DOSES OF PF07868489 IN HEALTHY ADULT PARTICIPANTS AND REPEAT DOSES IN PARTICIPANTS WITH PULMONARY ARTERIAL HYPERTENSION No dispute reported 06/30/2026 1228772250
Principal investigator 1 United Therapeutics Corporation $3,236.40 07/23/2025 Non-covered Recipient Entity
Norton Healthcare Inc
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242387073
Principal investigator 1 United Therapeutics Corporation $3,018.24 07/08/2025 Non-covered Recipient Entity
Norton Healthcare Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242387057
Principal investigator 1 United Therapeutics Corporation $3,064.32 07/08/2025 Non-covered Recipient Entity
Norton Healthcare Inc
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242387071
Principal investigator 1 Merck Sharp & Dohme LLC $16,355.00 07/07/2025 Non-covered Recipient Entity
Norton Pulmonary Specialists
A Phase 2, Multicenter, Single-blinded, Randomized Study to Evaluate the Pharmacokinetics and Safety of Sotatercept MK-7962 Administered Using Either a Weight-based or Weight-banded Approach in Participants With Pulmonary Arterial Hypertension PAH on No dispute reported 06/30/2026 1232938900
Principal investigator 1 Janssen Research & Development, LLC $130.00 07/03/2025 Non-covered Recipient Entity
COMMUNITY MEDICAL ASSOCIATES INC DB A NORTON NEUROSCIENCE INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175395806
Principal investigator 1 Janssen Research & Development, LLC $1,344.00 06/26/2025 Non-covered Recipient Entity
COMMUNITY MEDICAL ASSOCIATES INC DB A NORTON NEUROSCIENCE INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175395853
Principal investigator 1 United Therapeutics Corporation $1,908.67 06/25/2025 Non-covered Recipient Entity
Norton Healthcare Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242387053
Principal investigator 1 United Therapeutics Corporation $1,257.52 06/25/2025 Non-covered Recipient Entity
Norton Healthcare Inc
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242387065
Principal investigator 1 United Therapeutics Corporation $4,282.00 06/20/2025 Non-covered Recipient Entity
Norton Healthcare Inc
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242387083
Principal investigator 1 United Therapeutics Corporation $2,515.20 06/11/2025 Non-covered Recipient Entity
Norton Healthcare Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242387055
Principal investigator 1 United Therapeutics Corporation $12,655.00 06/11/2025 Non-covered Recipient Entity
Norton Healthcare Inc
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242387077
Principal investigator 1 United Therapeutics Corporation $25,110.40 06/11/2025 Non-covered Recipient Entity
Norton Healthcare Inc
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242387079
Principal investigator 1 Merck Sharp & Dohme LLC $6,456.87 06/06/2025 Covered Recipient Teaching Hospital
Norton Hospitals Inc
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection F No dispute reported 06/30/2026 1232938442
Principal investigator 1 Janssen Research & Development, LLC $1,444.00 05/26/2025 Non-covered Recipient Entity
COMMUNITY MEDICAL ASSOCIATES INC DB A NORTON NEUROSCIENCE INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175395836
Principal investigator 1 Janssen Research & Development, LLC $248.00 05/19/2025 Non-covered Recipient Entity
COMMUNITY MEDICAL ASSOCIATES INC DB A NORTON NEUROSCIENCE INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175395829
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,614.00 05/14/2025 Covered Recipient Teaching Hospital
Norton Hospitals Inc
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1236000462
Principal investigator 1 United Therapeutics Corporation $1,162.63 05/07/2025 Non-covered Recipient Entity
Norton Healthcare Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242387045
Principal investigator 1 United Therapeutics Corporation $1,425.28 05/07/2025 Non-covered Recipient Entity
Norton Healthcare Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242387047
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $225.00 04/28/2025 Non-covered Recipient Entity
Norton Pulmonary Specialists
BAY 632521, RiOciguAt UseRs Registry The ROAR registry No dispute reported 06/30/2026 1225419745
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $12,984.72 04/28/2025 Non-covered Recipient Entity
Norton Pulmonary Specialists
BAY 632521, RiOciguAt UseRs Registry The ROAR registry No dispute reported 06/30/2026 1225419791
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $8,889.27 04/28/2025 Non-covered Recipient Entity
Norton Pulmonary Specialists
BAY 632521, RiOciguAt UseRs Registry The ROAR registry No dispute reported 06/30/2026 1225419821
Principal investigator 1 Janssen Research & Development, LLC $181.00 04/28/2025 Non-covered Recipient Entity
COMMUNITY MEDICAL ASSOCIATES INC DB A NORTON NEUROSCIENCE INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175395846
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,140.67 04/10/2025 Non-covered Recipient Entity
Norton Pulmonary Specialists
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1235995141
Principal investigator 1 United Therapeutics Corporation $838.40 04/09/2025 Non-covered Recipient Entity
Norton Healthcare Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242387043
Principal investigator 1 United Therapeutics Corporation $1,676.80 02/26/2025 Non-covered Recipient Entity
Norton Healthcare Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242387037
Principal investigator 1 United Therapeutics Corporation $1,908.67 02/12/2025 Non-covered Recipient Entity
Norton Healthcare Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242387039
Principal investigator 1 United Therapeutics Corporation $2,766.72 02/12/2025 Non-covered Recipient Entity
Norton Healthcare Inc
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1242387041
Principal investigator 1 Janssen Research & Development, LLC $1,629.00 02/10/2025 Non-covered Recipient Entity
COMMUNITY MEDICAL ASSOCIATES INC DB A NORTON NEUROSCIENCE INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175395819
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $36,671.22 01/30/2025 Covered Recipient Teaching Hospital
Norton Hospitals Inc
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis No dispute reported 06/30/2026 1236000460
Principal investigator 1 Janssen Research & Development, LLC $543.00 01/27/2025 Non-covered Recipient Entity
COMMUNITY MEDICAL ASSOCIATES INC DB A NORTON NEUROSCIENCE INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175395813